In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Role of tilt-table testing in syncope diagnosis and management

An article from the e-Journal of Cardiology Practice

Syncope (transient loss of consciousness due to transient global cerebral hypoperfusion characterised by rapid onset, short duration and spontaneous complete recovery) is a very common condition. Tilt-table testing (TTT) plays a major role during the evaluation of syncope patients, helps to differentiate syncope subtypes and to discriminate between syncope and other common conditions such as epilepsy, and could be useful in guiding treatment. Nevertheless, TTT is still underutilised in many centres, and syncope patients are often subjected to a large number of different diagnostic tests which significantly increase health costs and have little diagnostic yield.

Syncope and Bradycardia


Syncope definition and classification

Transient loss of consciousness (TLOC), commonly referred to as fainting, encompasses not only syncope, but also epileptic seizures, psychogenic and other rare miscellaneous causes. What differentiates syncope from other forms of TLOC is its pathophysiology, including transient global cerebral hypoperfusion due to low peripheral resistances and/or low cardiac output. [1]

Current syncope classification, established by the European Society of Cardiology (ESC), is a pathophysiological one and distinguishes three main categories of syncope: reflex/neurally mediated syncope (vasovagal, situational, carotid sinus syncope and atypical forms); syncope due to orthostatic hypotension (primary or secondary autonomic failure, drug-induced orthostatic hypotension, volume depletion); and cardiac syncope (due to arrhythmia or structural disease). [2] Based on the recent increase in the ability to document spontaneous syncope episodes, there is also a new classification differentiating syncope in relation to the underlying mechanism: bradycardia, tachycardia and no or slight rhythm variations (hypotension). [1]

Epidemiology and prognosis

TLOC/syncope is extremely common in the general population with a cumulative incidence of first syncope episode around 10% up to 80 years. [1-3] The outcome of patients with syncope is related more to the severity of the underlying condition rather than to the syncope episode itself. In the absence of structural or electrical heart disease, the prognosis regarding risk of death and life-threatening events is generally excellent, [3] although the risk of syncope recurrences and physical injuries may still persist. [4]

Diagnostic algorithm

There are different diagnostic tests which should be applied for patients with TLOC, but their main purpose is to provide answers to two questions: 1) What is the prognosis (regarding death, serious adverse events and recurrences), and 2) What is the specific cause and is there an effective specific treatment strategy? [1,2] Initial assessment includes history, physical examination and ECG, followed by initial risk stratification and additional diagnostic tests, if appropriate. These include tilt-table testing (TTT), carotid sinus massage, ECG monitoring (in-hospital, Holter monitor, implantable loop recorders, telemetry), echocardiography, exercise stress testing, electrophysiological study, cardiac catheterization, neurological evaluation (electroencephalography, computed tomography and magnetic resonance imaging, neurovascular studies), and psychiatric evaluation.

Tilt-table test in the diagnosis of TLOC

Tilt-testing enables the reproduction of reflex syncope in a laboratory setting. Positive responses in patients with neurally mediated syncope are 61%-69%, and specificity is high (92%-94%). [2] The most commonly used protocol includes tilting to 70°, a passive unmedicated phase of 20 minutes, application of 300μg-400 μg sublingual nitroglycerine at the 20th minute and an additional 20 minutes of standing. [5]

The most common indication for TTT is to confirm a diagnosis of reflex syncope in patients in whom this diagnosis has been suspected but not confirmed by the initial evaluation. [2] This includes cases with a single unexplained syncope in a high-risk setting or those with multiple recurrent episodes when a cardiovascular cause has been reasonably excluded. TTT is also recommended when it is of clinical value to demonstrate susceptibility of the patient to reflex syncope.

Other indications for tilt-testing are discrimination between reflex syncope and orthostatic hypotension [6] or falls, [7] between TLOC with jerking movements and epilepsy, [8] and in patients with frequent episodes of TLOC and suspicion of psychiatric problems. [9]

According to the induction of syncope and blood pressure (BP) and heart rate (HR) reactions, there could be several types of response to tilting [10] – Table 1.

Table 1. Different Types of Response to Tilt-Testing.

Response/Diagnosis

Characteristics

Vasodepressor syncope

BP falls to a systolic value <60 mmHg. HR during syncope does not fall by more than 10% of its peak value.

Cardioinhibitory syncope without asystole

HR decreases <40 beats/min. for more than 10 sec; without asystole >3 sec. BP decreases before HR fall.

Cardioinhibitory syncope with asystole Asystole >3 sec.; decrease in HR precedes or coincides with BP fall.
Mixed syncope HR decreases during syncope but does not reach <40 beats/min., or reaches <40 beats/min. for <10 sec., with or without asystole <3 sec. BP decreases before HR fall.
Initial orthostatic hypotension Decrease in BP >40 mmHg at standing with spontaneous and fast normalization, so that hypotension and symptoms last <30 sec.
Classic orthostatic hypotension Decrease in systolic BP ≥20 mmHg and diastolic BP ≥10 mmHg during the first 3 min. after standing.
Late (progressive) orthostatic hypotension Slow and progressive systolic BP decline after the 3rd min. of standing.
POTS Increase in HR >30 beats/minutes or HR >120 beats/minute after standing, accompanied by symptoms and BP variability.
Negative TTT Syncope, orthostatic hypotension or POTS are not provoked.

POTS: postural orthostatic tachycardia syndrome

Compared with other diagnostic tests, TTT has one of the highest diagnostic yields if the result is abnormal, with the test being diagnostic in more than 50% of cases. [11,12] However, this is the situation which exists in specialized syncope centres and units, where a diagnosis can be established in more than 50% of patients with a mean of three tests per patient. [11,12]

Role of tilt-testing in patient management

There have been concerns that the diagnostic utility of TTT is not high enough, and that a positive TTT suggests the presence of hypotensive susceptibility rather than providing a diagnosis of reflex syncope. [13] However, performing tilt-testing according to ESC guidelines could have a high diagnostic yield (higher than most of the other tests).

Occurrence and recurrence of TLOC could have a major impact on a patient’s well-being and social adaptation. Most of the tests initially performed on these patients (mostly in general practices and not in dedicated syncope units) do not yield any positive results. It is still widespread practice to refer such cases to a neurologist who will perform different tests to exclude epilepsy, which can be additionally frustrating for the patient. Generally, these tests have a much lower diagnostic yield compared with tilt-testing. In such a situation, the ability to apply a simple and non-invasive test (like TTT) which could confirm the diagnosis of the most common syncope type – reflex syncope – is of great value.

The type of response to tilt-testing could guide patient management. Patients with vasodepressor and mixed syncope and those with orthostatic hypotension most of all need reassurance regarding the benign nature of the condition. [2] Education plays a key role in this setting and includes avoidance of triggering factors, an increase in fluid intake, physical counterpressure maneuvers [14] and tilt-training. [15]

The proper management for patients with cardioinhibitory syncope with asystole has been the subject of much debate. The question here is if pacing would reduce syncope recurrences. Several randomized controlled trials based on tilt-testing response have given conflicting results. [16-19] The International Study on Syncope of Uncertain Etiology (Issue-2)  showed a striking reduction in the recurrence of syncope with pacing in patients with documented asystole during spontaneous syncope (implantable loop recorder monitoring). [20] Issue-2 was a nonrandomised trial, but recently its results were confirmed by the randomised Issue-3. [21]

At present, the issue regarding the appropriateness of pacing patients with TTT-induced asystole during syncope is not fully resolved. The decision to implant a pacemaker (an invasive procedure) should be taken in the clinical context of a benign (in terms of mortality) condition that usually affects young individuals and often children. My personal experience (including children) is to refer patients with TTT-induced asystole during syncope to pacing only as a last resort and in cases of profound asystole (>6 sec). [22,23]

 

References


  1. Brignole M., & Hamdan M. H. New Concepts in the Assessment of Syncope. J Am Coll Cardiol, 2012. 59 (18): 1583-91.
  2. Moya A., Sutton R., Ammirati F., Blanc J. J., Brignole M., Dahm J. B., Deharo J. C., Gajek J., Gjesdal K., Krahn A., Massin M., Pepi M., Pezawas T., Ruiz Granell R., Sarasin F., Ungar A., van Dijk J. .G, Walma E. P., & Wieling W. Guidelines for the diagnosis and management of syncope (version 2009). Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS), Eur Heart J, 2009, Nov. 30 (21): 2631-71.
  3. Soteriades E. S., Evans J. C., Larson M. G., Chen M. H., Chen L., Benjamin E. J., & Levy D. Incidence and prognosis of syncope. N Engl J Med, 2002. 34 (12) 7: 878–85.
  4. Task force members: Brignole M., Vardas P., Hoffman E., Huikuri H., Moya A., Ricci R., Sulke N., & Wieling W. EHRA Scientific Documents Committee: Auricchio A., Lip G. Y., Almendral J., Kirchhof P., Aliot E., Gasparini M., & Braunschweig F. Document Reviewers: Lip G. Y., Almendral J., Kirchhof P., & Botto G. L. EHRA Scientific Documents Committee. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace, 2009, May 11 (5): 671-87.
  5. Benditt D. G., Ferguson D. W., Grubb B. P., Kapoor W. N., Kugler J., Lerman B. B., Maloney J. D., Raviele A., Ross B., Sutton R., Wolk M. J., & Wood D. L. Tilt-table testing for assessing syncope. American College of Cardiology. J Am Coll Cardiol, 1996. 28 (1): 263-75.
  6. Podoleanu C., Maggi R., Brignole M., Croci F., Incze A., Solano A., Puggioni E., & Carasca E. Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. J Am Coll Cardiol, 2006. 48 (7): 1425-32.
  7. Heitterachi E., Lord S. R., Meyerkort P., McCloskey I., & Fitzpatrick R. Blood pressure changes on upright tilting predict falls in older people. Age Ageing, 2002. 31 (3): 181-6.
  8. Zaidi A., Clough P., Cooper P., Scheepers B., & Fitzpatrick A. P. Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol, 2000. 36 (1): 181-4.
  9. Petersen M. E., Williams T. R., & Sutton R. Psychogenic syncope diagnosed by prolonged head-up tilt testing. QJM, 1995. 88 (3): 209-13.
  10. Brignole M., Menozzi C., Del Rosso A., Costa S., Gaggioli G., Bottoni N., Bartoli P., & Sutton R. New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification. Analysis of the pre-syncopal phase of the tilt test without and with nitroglycerin challenge. Europace, 2000. 2 (1): 66-76.
  11. Brignole M., Menozzi C., Bartoletti A., Giada F., Lagi A., Ungar A., Ponassi I., Mussi C., Maggi R., Re G., Furlan R., Rovelli G., Ponzi P., & Scivales A. A new management of syncope: prospective systematic guideline-based evaluation of patients referred urgently to general hospitals. Eur Heart J, 2006. 27 (1): 76-82.
  12. Brignole M., Ungar A., Casagranda I., Gulizia M., Lunati M., Ammirati F., Del Rosso A., Sasdelli M., Santini M., Maggi R., Vitale E., Morrione A., Francese G. M., Vecchi M. R., & Giada F.  Syncope Unit Project (SUP) investigators. Prospective multicentre systematic guideline-based management of patients referred to the syncope units of general hospitals. Europace, 2010. 12 (1): 109-18.
  13. Sutton R., & Brignole M. Twenty-eight years of research permit reinterpretation of tilt-testing: hypotensive susceptibility rather than diagnosis. Eur Heart J, 2014. 35 (33): 2211-2.
  14. van Dijk N., Quartieri F., Blanc J. J., Garcia-Civera R., Brignole M., Moya A., & Wieling W. PC-Trial Investigators. Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the Physical Counterpressure Manoeuvres Trial (PC-Trial). J Am Coll Cardiol, 2006. 48 (8): 1652-7.
  15. Duygu H., Zoghi M., Turk U., Akyuz S., Ozerkan F., Akilli A., Erturk U., Onder R., & Akin M. The role of tilt training in preventing recurrent syncope in patients with vasovagal syncope: a prospective and randomized study. Pacing Clin Electrophysiol, 2008. 31 (5): 592-6.
  16. Sutton R., Brignole M., Menozzi C., Raviele A., Alboni P., Giani P., & Moya A. Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope: pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators. Circulation, 2000. 102 (3): 294-9.
  17. Connolly S. J., Sheldon R., Roberts R. S., & Gent M. The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol, 1999. 33 (1): 16-20.
  18. Connolly S. J., Sheldon R., Thorpe K. E., Roberts R. S., Ellenbogen K. A., Wilkoff B. L., Morillo C., & Gent M. VPS II Investigators. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA, 2003. 289 (17): 2224-9.
  19. Raviele A., Giada F., Menozzi C., Speca G., Orazi S., Gasparini G., Sutton R., & Brignole M. Vasovagal Syncope and Pacing Trial Investigators. A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE). Eur Heart J, 2004. 25 (19): 1741-8.
  20. Brignole M., Sutton R., Menozzi C., Garcia-Civera R., Moya A., Wieling W., Andresen D., Benditt D. G., & Vardas P. International Study on Syncope of Uncertain Etiology 2 (Issue-2) Group. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J, 2006. 27 (9): 1085-92.
  21. Brignole M., Menozzi C., Moya A., Andresen D., Blanc J. J., Krahn A. D., Wieling W., Beiras X., Deharo J. C., Russo V., Tomaino M., & Sutton R. International Study on Syncope of Uncertain Etiology 3 (Issue-3) Investigators. Pacemaker therapy in patients with neurally-mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (Issue-3): a randomized trial. Circulation, 2012. 125 (21): 2566-71.
  22. Simova I., Katova T., Zerdeva E., Dasheva A., Levunlieva E., & Kuneva A. Syncope in children and adolescents. Role of tilt-table testing. Bulgarian Cardiology, 2014. 3 (ХХ): 35-40.
  23. Tilt-table testing in patients with syncope. Simova I., & Katova T. Oral presentation at XIII National Cardiology Congress, Sofia, 04-07.10, 2012. Bulgarian Cardiology, 2012. XVIII (suppl. 2): p. 57.

Notes to editor


Author:

Associate Professor Iana Simova, MD, PhD

Department of Noninvasive Cardiovascular Imaging and Functional Diagnostics, National Cardiology Hospital, Sofia, Bulgaria

email: ianasimova@gmail.com

Author’s disclosures: No conflicts of interest to declare.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.